| INTRODUCTION
Oxidative stress (OS) is due to an imbalance between the generation of reactive oxygen species (ROS) and their antioxidant scavengers.
1
Oxidative stress contributes to several diseases, including male infertility, and ROS have been detected in the semen samples of ~30-80% of infertile male patients. 2, 3 Recently, the presence of ROS in semen has been attributed to both activated leukocytes and defective spermatozoa. Leukocytes produce 1000-fold greater ROS than spermatozoa do. 4 The membrane of spermatozoa contains high levels of polyunsaturated fatty acids (PUFA) because they retain their fluidity in order to fuse to the oocyte membrane. The PUFA are weak if they are attacked by ROS. The peroxidation of PUFA in sperm induces a decline in sperm motility. 5, 6 Furthermore, ROS infiltrate into sperm and break down the sperm DNA. 7 These adverse effects of ROS result in a decrease in the natural pregnancy rate 8 and the fertilization rate of assisted reproductive technology. 9 As a result of a negative correlation between the ROS levels with sperm motility and fertilization, the ROS levels in semen could serve as an independent marker of male factor infertility, particularly in cases of idiopathic infertility. 10, 11 Numerous studies concerning ROS in semen have been reported. [6] [7] [8] [9] [10] [11] [12] Chemiluminescence assays are widely adopted in ROS measurement. 6, 8, [12] [13] [14] [15] [16] [17] Constant chemiluminescence after the addition of 5-a mino-2,3-dihydro-1,4-phthalazine-dione (luminol) to unprocessed or washed semen is measured with a luminometer. The authors previously had measured ROS in semen samples by using the 1251 Luminometer ™ (LKB Wallac, Turku, Finland); however, cuvettes were unavailable for ROS measurement with the 1251 Luminometer ™ . Nevertheless, it was possible to obtain the Monolight ™ 3010 Luminometer (BD Biosciences Pharmingen, Ltd., San Diego, CA, USA) and the necessary cuvettes.
To the authors' knowledge, no previous study has measured ROS in semen by using the Monolight ™ 3010 Luminometer. Therefore, ROS
were measured in the unprocessed semen samples of infertile male patients by using this device. This study aimed to determine whether ROS in whole semen samples could be measured with the Monolight ™ 3010 Luminometer.
| MATERIALS AND METHODS

| Semen samples and semen parameter assessment
All the participants provided written informed consent. This study's protocols were reviewed and approved by the Yokohama City University Review Board, Yokohama City, Japan.
Between February, 2013 and June, 2016, the semen samples from 715 infertile male patients (mean age: 36.9 years; range: 15-79 years) who visited Yokohama City University's Reproduction Center were studied. The azoospermic patients were excluded. The patients who were included had idiopathic infertility (n = 243), untreated varicoceles (n = 206), spermatogenic failure due to cancer chemotherapy (n = 51), an infertile female partner (n = 178), treated undescended testis (n = 13), and other causes of infertility (n = 24). Semen specimens were collected by masturbation after 48-120 hours of sexual abstinence.
The semen analyses were performed two or three times before treatment with the Sperm Motility Analyzing System (SMAS ™ ; DITECT, Ltd., Tokyo, Japan). 
| Statistical analysis
The statistical values are presented as the mean ± standard devia- 
| RESULTS
| Time course of chemiluminescence
When the chemiluminescence was measured with the Monolight ™ 3010 Luminometer, the luminescence level increased for several seconds and then decreased rapidly before the addition of luminol. When multiple measurements were performed on the same specimen, the chemiluminescence values were almost the same (data not shown).
Therefore, the data that were measured by using this study's method were reproducible and hence chemiluminesence measurement was performed once after the semen analysis. Moreover, the relationship between the time-course-curve pattern and the chemiluminescence value was investigated by using 190 sample data and the time course was recorded from the start of the study. The patients were diagnosed as having idiopathic infertility (n = 55), untreated varicocele (n = 80), spermatogenic failure due to cancer chemotherapy (n = 19), treatment of undescended testis (n = 2), or other causes (n = 6) and 29 had an infertile female partner. These 190 samples were divided into three groups, according to the time-course pattern after the addition of luminol. The luminescence level increased rapidly and then decreased slowly for 100-150 s in Group A (n = 62). The integral luminescence value of the samples in this group was 51.62 ± 166.89-fold higher than that observed before the addition of luminol. The luminescence level of the second sample group (Group B, n = 27) increased for several seconds and did not decrease during the measurement. The integral luminescence value of the samples in this group was 24.61 ± 31.84-fold higher than that measured before the addition of luminol. In Group C (n = 101), although the peak value increased, the pattern of the time course was similar to that before the addition of luminol ( Figure 2 ).
The integral luminescence value was 1.68 ± 0.57-fold higher than that measured before the addition of luminol (Table 1) . Table 2 
| Determinants of the threshold level of chemiluminescence
When the measured luminescence values were arranged in order from the lowest, all the samples exhibiting a luminescence value of F I G U R E 1 Reactive oxygen species (ROS), as measured by the chemiluminescence method with a 1251 Luminometer ™ . 16 When the peak level was ≥.1 mv/s, the ROS formation was considered to be positive. The integral level of ROS production was calculated by subtracting the area under the baseline from the total chemiluminescence values, between 0 and 30 minutes after the addition of 40 μL of 100 mmol of luminol to 500 μL of unprocessed semen, and expressed as mV/30 min 10 6 spermatozoa F I G U R E 2 Time course of luminescence in the unprocessed semen samples. Before the addition of 40 μL of 100 mmol of luminol, the luminescence value increased for several seconds, before decreasing rapidly. After the addition of luminol, a rapid increase and then a slow decline in the luminescence level occurred in Group A, a rapid increase and then the maintenance of luminescence during the measuring time occurred in Group B, and a course similar to that observed before the addition of luminol, but with a slight increase in the integral luminescence level, occurred in Group C (Table 3 ). In total, 315 (44.1%) samples were luminescence-detectable (over the threshold value) and 400 (55.9%) samples were luminescence-undetectable.
The semen volume, sperm motility, and progressive motility in 
motility (%)
Less than threshold (n = 400) Mean ± SD 
| Correlation of the luminescence levels measured by the 1251 Luminometer ™ and the
Monolight
™ 3010 Luminometer
The chemiluminescence values of the 84 samples were measured concurrently with the two luminometers and plotted to determine whether a correlation between the devices existed. The integrated luminescence level in the 84 semen samples, as measured by the Monolight 
| DISCUSSION
Oxidative stress is one of the major factors that could result in male infertility. The luminescence values of the samples with greater than the threshold level, converted to per 10 6 spermatozoa and logarithmically transformed, were negatively correlated with the semen motile parameters that were measured by the SMAS ™ , except the LIN. These results were similar to those of other reports on the correlation between ROS in semen and semen parameters. (Table 2 ; P = .065). This finding could be because F I G U R E 6 Chemiluminescence (mean ± standard deviation) value above the threshold level of the samples in each group of patients F I G U R E 5 Number of patients with a chemiluminescence value greater or less than the threshold level. The patients are categorized according to the cause of their infertility. P < .001, according to the chi-square test the dose of luminol (100 mmol L -1 , 40 μL) in the current study was higher than that in other reports. 6, 8, [13] [14] [15] 21 The authors assumed that increasing the dose of luminol would make ROS detection clearer and the authors adopted the luminol dose that was reported by a specific study. 16 However, in this study's results, the percentage of the semen samples in Groups A and B were 31.9 and 14.1%, respectively. In all the patients, the percentage of samples that had greater than the threshold level was 44.1%. These percentages were almost similar to those in other reports. Moreover, Figure 3 shows that the ranges of logarithmized ROS values of the samples in Groups A and B overlapped. Thus, it is believed that the detectable ROS in the Group B samples were not false-positives and that adversely affected sperm motility. As another cause, the proportion of the origin of ROS in each time-course-curve group might be different. The ROS in semen have been associated with activated leukocytes and defective spermatozoa. In addition, the time-course pattern difference might depend on the ratio of activated leukocytes to defective spermatozoa in the semen. The authors are conducting further investigations in order to elucidate this cause.
The integral value of chemiluminescence was defined 200 seconds after the addition of luminol as the total amount of ROS because the authors consider that the integral ROS level reflects the effect of ROS on spermatozoa. The authors have adopted this method since starting measuring ROS using the 1251 Luminometer ™ .
6,8,16
The samples were classified according to the cause of male infertility and the ROS detection rate of each group and the ROS value was compared. The ROS was detected in 27.5% of the patients with an infertile female partner ( Figure 5 ). In the authors' department, gynecologists advised the male partners with abnormal semen findings in order to seek a consultation with the urological specialists. However, not all of the advised men underwent urological investigation. Those patients who did were assigned to one of the aforementioned male causes of infertility, while the remainder was included in the "male with an infertile female partner" group. Seminal findings might be normal and abnormal in these patients and the inclusion of those with male factors was possible. Therefore, ROS-detectable patients could have been included in the group that was composed of men with an infertile female partner. Nevertheless, numerous patients in this group had good semen findings or mildly reduced ones; thus, the ROS detection rate was low and the value of positive cases was estimated to be significantly low. Moreover, the difference in the ROS detection rate among the patients who were grouped according to male causes was noted ( Figure 6 ). Not all infertile male patients are affected by OS. The degree of OS involvement seems to be different, depending on the disease.
Lastly, the consistency of ROS was measured by the two devices. Although both devices measured chemiluminescence that was initiated by luminol, the unit for the luminescence values in the 1251 Luminometer ™ was mv, while that in the Monolight ™ 3010
Luminometer was RLU. Furthermore, the measuring time of both The ROS in semen correlates with sperm motility and fertility [1] [2] [3] [6] [7] [8] [9] [10] [11] [12] 16 and ROS might be one of the most effective biomarkers of male infertility. 10, 11 Recently, due to advances in proteomics, a number of candidate biomarkers of male infertility have been reported. 22, 23 However, no candidate biomarker could surpass ROS.
Although ROS could be one of the most effective biomarkers of male infertility, 10 ROS are not routinely measured in clinical practice to investigate male infertility. Nevertheless, ROS tests, as sperm function tests in research procedures, were published in the latest World Health Organization laboratory manual. 24 However, one study stated that despite its potential to provide additional prognostic information, ROS testing is not commonly performed during the initial assessment of male fertility because of its high cost, inconvenience, and lack of efficiency. 
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